990175-8
IPOS Copy

CORRECTED VERSION*

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
A61K 39/395, 38/17, 38/55 // C07K 19/00, (A61K 39/395, 38:17) (A61K 38/55, 38:17)

A3

(11) International Publication Number: WO 98/17313

(43) International Publication Date: 30 April 1998 (30.04.98)

(21) International Application Number: PCT/US97/19436

(22) International Filing Date: 24 October 1997 (24.10.97)

(30) Priority Data:
60/029,060 25 October 1996 (25.10.96) US

(71) Applicant *(for all designated States except US)*: BIOGEN, INC. [US/US]; 14 Cambridge Center, Cambridge, MA 02142 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: BROWNING, Jeffrey [US/US]; 32 Milton Road, Brookline, MA 02146 (US). HOCHMAN, Paula, Susan [US/US]; 14 White Avenue, Newton, MA 02159 (US). RENNERT, Paul, D. [US/US]; 2 Skyview Terrace, Holliston, MA 01746 (US). MacKAY, Fabienne [US/US]; 126 Church Street, Watertown, MA 02172 (US).

(74) Agent: FLYNN, Kerry, A.; Biogen, Inc., 14 Cambridge Center, Cambridge, MA 02142 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(88) Date of publication of the international search report:
30 July 1998 (30.07.98)

(54) Title: SOLUBLE LYMPHOTOXIN-BETA RECEPTORS, ANTI-LYMPHOTOXIN RECEPTOR ANTIBODIES, AND ANTI-LYMPHOTOXIN LIGAND ANTIBODIES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF IMMUNOLOGICAL DISEASES

(57) Abstract

Compositions and methods comprising "lymphotoxin-β receptor blocking agents" which block lymphotoxin-ß receptor signalling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.